Monday, June 15, 2026

Why Are North Korea’s Grain Management Facilities Lagging? Analyzing Kim Jong-un’s 2024 Agricultural Strategy

Kim Jong Un's grain management centers face delays due to prioritization of other projects, raising concerns about North Korea's food distribution system.

Why Wasn’t Tesla a Part of the ‘NVIDIA party’?

NVIDIA announced earnings that exceeded market expectations, sparking an artificial intelligence (AI) rally on Wall Street.

North Korea Burns Anti-Regime Leaflets: A Bold Statement or a Dangerous Escalation?

News1On July 15, the South Korean Ministry of Unification noted it as unusual that Kim Yo Jong, Depu ...

Jung Eun Kim

Author's Latest

South Korea’s Pharmaceutical Future: 500 Million USD Investment from Eli Lilly to Boost K-Bio Innovation

South Korea partners with Eli Lilly to boost biotech and pharma industries, investing $500M to enhance innovation and healthcare access.

How Keytruda is Revolutionizing Cancer Treatment: Expanded Coverage for Stomach Cancer in 2026

Keytruda's insurance coverage expands to stomach cancer, solidifying its status as a leading universal immunotherapy for various cancers.

Ubicare Targets 80%+ Operating Profit Growth in 2026 — Here’s What’s Changing in Its EMR and Platform Play

Ubicare reported a 46% increase in operating profit for 2025, driven by optimized revenue structures and plans for AI solutions in 2026.

How Lunit’s AI is Transforming Early Breast Cancer Risk Assessment: Key Findings from ECR 2026

Lunit presents 21 research findings at ECR 2026, showcasing AI's potential in breast cancer risk assessment and screening innovations.

A New Adult Pneumococcal Shot Hits Korea: 21-Valent Coverage Targeting 80% of Adult Invasive Cases

Korean MSD launches Capvaxive, a 21-valent vaccine for adults to prevent pneumococcal diseases, targeting high-risk populations.

Will Novo Nordisk’s 50% Price Cut on Wegovy Spark a Price War in Korea’s Obesity Drug Market?

Novo Nordisk's price cuts for GLP-1 obesity treatments in the U.S. may influence South Korean market dynamics, though immediate effects seem limited.

Korean Health Insurance Corporation Wins Platinum Award for Sustainability Report: What This Means for ESG Practices

NHIS wins Platinum Award at LACP Vision Awards for its sustainability report, achieving a perfect score in seven categories.

ABL209 Receives FDA Approval: What This Dual Antibody ADC Means for Cancer Treatment

ABL Bio receives FDA approval for ABL209, a bispecific antibody-drug conjugate, advancing ADC development for solid tumors.

Korea’s Olive Young Gets a New Sleep Aid: Daewon Launches Honey Sleep Shot Backed by a Study

Daewon Health launches Honey Sleep Shot, a plant-based sleep aid, in 900 Olive Young stores, targeting sleep issues for modern consumers.

Novo Nordisk Slashes GLP-1 Drug Prices by Up to 50%: What This Means for Obesity Treatments in 2027

Novo Nordisk will cut prices of GLP-1 treatments in the U.S. by up to 50% from January 2027, amid rising competition and market pressures.

GCCell Secures Groundbreaking Patent for Next-Gen Cell Therapy: What It Means for the Future of Immunotherapy

GC Cell has completed the registration of core technology patents for next-gen cell and gene therapies in South Korea and Japan.

Unlocking Weight Loss: How Celltrion’s New CT-G32 and Oral Multi-Action Drug Will Change the Game

Celltrion aims to lead the obesity treatment market with innovative drugs, enhancing efficacy and patient convenience through dual approaches.

A New Hair-Growth Pathway?: JW0061 Targets GFRA1 After 7.2x Organoid Results and a 39% Animal Boost

JW Pharmaceutical's hair loss treatment JW0061 gains FDA approval for clinical trials, promising innovative growth stimulation for men and women.

CT-P55: How Celltrion’s New Biosimilar Approval Will Transform Clinical Trials in Europe

Celltrion receives EMA approval to reduce patient enrollment for CT-P55 trial, aiming to cut costs and duration of clinical development.

Top News

- Our Sponsors Ad -

Follow us

Cars

Tech

future

health

© Copyright by News1. All Rights Reserved.